Cost-effectiveness of PET imaging in clinical oncology

Valk, Peter E.; Pounds, Thomas R.; Tesar, Ruth; Hopkins, Donald M.; Haseman, Michael K.

doi:10.1016/0969-8051(96)00080-7

Cited by 184 publications

(63 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a cohort consisting of 45 patients with recurrent melanoma, PET was able to detect previously unknown distant metastases in 27% of patients or could assign suggestive lesions as benign (28). Curative surgical intervention was cancelled, resulting in cost saving of $2,175 per patient.…”

Section: Other Solid Neoplasmsmentioning

confidence: 99%

“…Costs for fine-needle biopsy and thoracotomy can be prevented if a suggestive lesion can be reliably classified as benign. In a case-tracking study, Valk et al reported that the use of PET has led to a reduction of costs of $2,200 per patient (28). A second research group in the United States reported cost savings of $91-$2,200 per patient if the standard diagnostic algorithm consisting of CT only is supplemented by PET (CT 1 PET strategy) (29).…”

Section: Differential Diagnosis Of Solitary Pulmonary Nodulesmentioning

confidence: 99%

“…Valk et al prospectively evaluated patients with resectable head and neck cancer or local tumor recurrence (28). Detection of distant metastases led to cancellation of curative surgery and resulted in a cost saving of $500 per patient.…”

Section: Head and Neck Cancersmentioning

confidence: 99%

“…The ratio of additional costs for a PETbased imaging algorithm and the saving of additional lifeyears based on decision models has been evaluated in only a few studies. For the assessment of cost-effectiveness, 2 studies considered the reimbursement policy of the U.S. health care system (28,38), whereas a third study considered the regulations of the French health care system (39). In patients with recurrent colorectal cancer and suspicion of hepatic metastases, Gambhir et al compared various diagnostic algorithms, including a combination of the tumor marker carcinoembryonic antigen and CT scan (carcinoembryonic antigen 1 CT) or the additional use of PET (carcinoembryonic antigen 1 CT 1 PET) (40).…”

Section: Colorectal Cancermentioning

confidence: 99%

See 3 more Smart Citations

Economic Evaluation of PET and PET/CT in Oncology: Evidence and Methodologic Approaches

Buck¹,

Herrmann²,

Stargardt³

et al. 2010

Journal of Nuclear Medicine Technology

107

View full text Add to dashboard Cite

PET and PET/CT have changed the diagnostic algorithm in oncology. Health care systems worldwide have recently approved reimbursement for PET and PET/CT for staging of non-small cell lung cancer and differential diagnosis of solitary pulmonary nodules because PET and PET/CT have been found to be cost-effective for those uses. Additional indications that are covered by health care systems in the United States and several European countries include staging of gastrointestinal tract cancers, breast cancer, malignant lymphoma, melanoma, and head and neck cancers. Regarding these indications, diagnostic effectiveness and superiority over conventional imaging modalities have been shown, whereas cost-effectiveness has been demonstrated only in part. This article reports on the current knowledge of economic evaluations of PET and PET/CT in oncologic applications. Because more economic evaluations are needed for several clinical indications, we also report on the methodologies for conducting economic evaluations of diagnostic tests and suggest an approach toward the implementation of these tests in future clinical studies.

show abstract

Section: Other Solid Neoplasmsmentioning

confidence: 99%

Section: Differential Diagnosis Of Solitary Pulmonary Nodulesmentioning

confidence: 99%

Section: Head and Neck Cancersmentioning

confidence: 99%

Section: Colorectal Cancermentioning

confidence: 99%

See 2 more Smart Citations

Economic Evaluation of PET and PET/CT in Oncology: Evidence and Methodologic Approaches

Buck¹,

Herrmann²,

Stargardt³

et al. 2010

Journal of Nuclear Medicine Technology

107

View full text Add to dashboard Cite

show abstract

“…7. Moreover, 18 FDG itself is (becoming) the most frequently used clinical application of PET in oncology which is also due to the fact that a number of studies have shown that this application of PET is cost effective and patient friendly [28][29][30]. In fact, due to the fact that 18 FDG can be transported over distances of roughly 2 hours, many stand-alone PET scanners are being installed which are served from regional 18 FDG 'factories'.…”

Section: Applications In Oncologymentioning

confidence: 99%

Positron emission tomography

Paans¹

2002

Methods

View full text Add to dashboard Cite

Advances in Biomedical Imaging

Tempany

McNeil²

2001

JAMA

131

View full text Add to dashboard Cite

In the 21st century, diseases will be diagnosed and treated using increasingly less invasive, more sophisticated imaging and image-guided procedures. During the past 100 years, the field of biomedical imaging has developed from Roentgen's original discovery of the x-ray to the imaging tools of today, such as magnetic resonance imaging, computed tomography, positron emission tomography, and ultrasonography. The benefits of using these sophisticated noninvasive imaging tools are already evident: more accurate and timely diagnosis of disease has translated into improved patient care. Recent advances in imaging research have shown the potential to change many aspects of clinical medicine within the next decade. Major new areas of research focus on development of the molecular, functional, cellular, and genetic imaging tools of the future, aided by new information technology and image fusion/integration capabilities. Image-guided therapy is growing rapidly, with advances in computer science, technology, and noninvasive treatment methods, such as focused ultrasonography. Undoubtedly, these and other new imaging techniques will enhance the ability to accurately diagnose and recognize disease and allow understanding of the molecular mechanisms of diseases and their respective responses to therapy. Given this explosion in new technologies, the next 25 years promise to result in dramatic changes in diagnostic imaging, particularly with respect to detection and recognition of disease.

show abstract

Cost-effectiveness of PET imaging in clinical oncology

Cited by 184 publications

References 15 publications

Economic Evaluation of PET and PET/CT in Oncology: Evidence and Methodologic Approaches

Economic Evaluation of PET and PET/CT in Oncology: Evidence and Methodologic Approaches

Positron emission tomography

Advances in Biomedical Imaging

Contact Info

Product

Resources

About